See more : Vista Outdoor Inc. (VSTO) Income Statement Analysis – Financial Results
Complete financial analysis of Cue Biopharma, Inc. (CUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cue Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Zhongsheng Group Holdings Limited (0881.HK) Income Statement Analysis – Financial Results
- Midsona AB (publ) (9KF.F) Income Statement Analysis – Financial Results
- Digi International Inc. (DGII) Income Statement Analysis – Financial Results
- Braskem S.A. (BRKM6.SA) Income Statement Analysis – Financial Results
- Molecure S.A. (MOC.WA) Income Statement Analysis – Financial Results
Cue Biopharma, Inc. (CUE)
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.49M | 1.25M | 14.94M | 3.15M | 3.46M | 1.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 38.10M | 1.81M | -1.78M | 33.55M | 27.49M | 28.54M | 419.57K | 202.09K | 44.82K |
| Gross Profit | -32.61M | -560.83K | 16.72M | -30.39M | -24.03M | -27.40M | -419.57K | -202.09K | -44.82K |
| Gross Profit Ratio | -593.93% | -45.04% | 111.90% | -963.48% | -694.90% | -2,398.16% | 0.00% | 0.00% | 0.00% |
| Research & Development | 40.80M | 38.58M | 41.35M | 33.55M | 27.49M | 28.54M | 18.90M | 5.69M | 1.50M |
| General & Administrative | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.68M | 16.17M | 17.31M | 14.65M | 12.74M | 11.30M | 4.33M | 1.97M | 425.08K |
| Other Expenses | -37.94M | 0.00 | 0.00 | 0.00 | 64.00K | 165.34K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.54M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Cost & Expenses | 57.64M | 54.75M | 58.65M | 48.20M | 40.23M | 39.84M | 23.23M | 7.66M | 1.93M |
| Interest Income | 2.66M | 928.24K | 45.90K | 463.91K | 419.00K | 376.01K | 35.00 | 52.00 | 0.00 |
| Interest Expense | 1.25M | 713.82K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.44M | 1.81M | -1.78M | 1.06M | 5.35M | 760.01K | 419.57K | 202.09K | 44.82K |
| EBITDA | -46.05M | -50.49M | -45.44M | -43.99M | -35.96M | -37.94M | -22.81M | -7.46M | -1.88M |
| EBITDA Ratio | -838.83% | -4,076.94% | -292.56% | -1,394.44% | -1,063.30% | -3,320.19% | 0.00% | 0.00% | 0.00% |
| Operating Income | -52.15M | -53.22M | -43.71M | -45.04M | -36.77M | -38.70M | -23.23M | -7.66M | -1.93M |
| Operating Income Ratio | -949.89% | -4,274.31% | -292.56% | -1,427.96% | -1,063.30% | -3,386.71% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 215.00K | 45.90K | 463.91K | 482.79K | 541.35K | 35.00 | 52.00 | 0.00 |
| Income Before Tax | -50.73M | -53.01M | -43.67M | -44.58M | -36.29M | -38.16M | -23.23M | -7.66M | -1.93M |
| Income Before Tax Ratio | -924.10% | -4,257.09% | -292.25% | -1,413.26% | -1,049.33% | -3,339.33% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -214.43K | 495.00K | 206.25K | 412.00K | 825.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -50.73M | -52.80M | -44.16M | -44.78M | -36.70M | -38.98M | -23.23M | -7.66M | -1.93M |
| Net Income Ratio | -924.10% | -4,239.87% | -295.56% | -1,419.79% | -1,061.25% | -3,411.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| EPS Diluted | -1.11 | -1.48 | -1.41 | -1.56 | -1.66 | -1.94 | -1.13 | -0.37 | -0.09 |
| Weighted Avg Shares Out | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
| Weighted Avg Shares Out (Dil) | 45.75M | 35.65M | 31.29M | 28.69M | 22.04M | 20.13M | 20.64M | 20.64M | 20.64M |
Vident Investment Advisory LLC Acquires New Stake in Cue Biopharma Inc (NASDAQ:CUE)
Morgan Stanley Has $556,000 Stock Position in Cue Biopharma Inc (NASDAQ:CUE)
Third Federal Savings and Loan Association of Cleveland, MHC Members Approve Dividend Waiver
Nuveen Asset Management LLC Sells 44,220 Shares of Cue Biopharma Inc (NASDAQ:CUE)
Politics and Policy: Drug firms called to embrace concept of public goods
From hockey poster boy to forlorn star
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings
Source: https://incomestatements.info
Category: Stock Reports